Cargando…
Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645566/ http://dx.doi.org/10.1186/2051-1426-3-S2-O7 |
| _version_ | 1782400841604399104 |
|---|---|
| author | Gangadhar, Tara C Hamid, Omid Smith, David C Bauer, Todd M Wasser, Jeffrey S Luke, Jason J Balmanoukian, Ani S Kaufman, David R Zhao, Yufan Maleski, Janet Leopold, Lance Gajewski, Thomas F |
| author_facet | Gangadhar, Tara C Hamid, Omid Smith, David C Bauer, Todd M Wasser, Jeffrey S Luke, Jason J Balmanoukian, Ani S Kaufman, David R Zhao, Yufan Maleski, Janet Leopold, Lance Gajewski, Thomas F |
| author_sort | Gangadhar, Tara C |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645566 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46455662015-11-20 Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers Gangadhar, Tara C Hamid, Omid Smith, David C Bauer, Todd M Wasser, Jeffrey S Luke, Jason J Balmanoukian, Ani S Kaufman, David R Zhao, Yufan Maleski, Janet Leopold, Lance Gajewski, Thomas F J Immunother Cancer Oral Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645566/ http://dx.doi.org/10.1186/2051-1426-3-S2-O7 Text en Copyright © 2015 Gangadhar et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Gangadhar, Tara C Hamid, Omid Smith, David C Bauer, Todd M Wasser, Jeffrey S Luke, Jason J Balmanoukian, Ani S Kaufman, David R Zhao, Yufan Maleski, Janet Leopold, Lance Gajewski, Thomas F Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers |
| title | Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers |
| title_full | Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers |
| title_fullStr | Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers |
| title_full_unstemmed | Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers |
| title_short | Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers |
| title_sort | preliminary results from a phase i/ii study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645566/ http://dx.doi.org/10.1186/2051-1426-3-S2-O7 |
| work_keys_str_mv | AT gangadhartarac preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT hamidomid preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT smithdavidc preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT bauertoddm preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT wasserjeffreys preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT lukejasonj preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT balmanoukiananis preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT kaufmandavidr preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT zhaoyufan preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT maleskijanet preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT leopoldlance preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers AT gajewskithomasf preliminaryresultsfromaphaseiiistudyofepacadostatincb024360incombinationwithpembrolizumabinpatientswithselectedadvancedcancers |